Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
- 15 June 2015
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 65 (24), 2638-2651
- https://doi.org/10.1016/j.jacc.2015.05.001
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin TherapyCirculation, 2013
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Twenty-Two–Year Trends in Incidence of Myocardial Infarction, Coronary Heart Disease Mortality, and Case Fatality in 4 US Communities, 1987–2008Circulation, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- PCSK9 as a therapeutic target of dyslipidemiaEmerging Therapeutic Targets, 2008
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences of the United States of America, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences of the United States of America, 2003
- Genetic Localization to Chromosome 1p32 of the Third Locus for Familial Hypercholesterolemia in a Utah KindredArteriosclerosis, Thrombosis, and Vascular Biology, 2000